Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres

Respirology. 2016 Feb;21(2):329-37. doi: 10.1111/resp.12714. Epub 2015 Dec 28.

Abstract

Background and objective: In cystic fibrosis (CF), chronic Pseudomonas aeruginosa infection is associated with increased morbidity, antibiotic treatments and mortality. By linking Australian CF registry data with a national microbiological data set, we examined the association between where treatment was delivered, its intensity and P. aeruginosa antibiotic resistance.

Methods: Sputa were collected from paediatric and adult CF patients attending 18 Australian CF centres. P. aeruginosa antibiotic susceptibilities determined by local laboratories were correlated with clinical characteristics, treatment intensity and infection with strains commonly shared among Australian CF patients. Between-centre differences in treatment and antibiotic resistance were also compared.

Results: Large variations in antibiotic usage, maintenance treatment practices and multi-antibiotic resistant P. aeruginosa (MARPA) prevalence exist between Australian CF centres, although the overall proportions of MARPA isolates were similar in paediatric and adult centres (31% vs 35%, P = 0.29). Among paediatric centres, MARPA correlated with intravenous antibiotic usage and the Australian state where treatment was delivered, while azithromycin, reduced lung function and treating state predicted intravenous antibiotic usage. In adult centres, body mass index (BMI) and treating state were associated with MARPA, while intravenous antibiotic use was predicted by gender, BMI, dornase-alpha, azithromycin, lung function and treating state. In adults, P. aeruginosa strains AUST-01 and AUST-02 independently predicted intravenous antibiotic usage.

Conclusion: Increased treatment intensity in paediatric centres and the Australian state where treatment was received are both associated with greater risk of MARPA, but not worse clinical outcomes.

Keywords: Pseudomonas aeruginosa; antibiotic resistance; cystic fibrosis; epidemiology; treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravenous
  • Adult
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use*
  • Australia
  • Azithromycin / therapeutic use
  • Body Mass Index
  • Child
  • Cystic Fibrosis / complications*
  • Cystic Fibrosis / physiopathology
  • Drug Resistance, Multiple, Bacterial*
  • Drug Utilization
  • Female
  • Health Facilities*
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Practice Patterns, Physicians'
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas aeruginosa / drug effects*
  • Registries
  • Respiratory Function Tests
  • Sex Factors
  • Sputum / microbiology

Substances

  • Anti-Bacterial Agents
  • Azithromycin